Most Read Articles
Elvira Manzano, 2 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 2 days ago
For individual with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.

PD-1, PD-L1 inhibition effective against metastatic urothelial carcinoma

27 Nov 2019

Inhibitors against programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) provide comparable survival benefits in patients with platinum-resistant metastatic urothelial cancer (mUC), reports a recent meta-analysis.

Accessing the databases of Pubmed, Medline, Scopus and the Cochrane Register for Controlled trials, researchers retrieved phase I, II and III clinical trials that investigated the efficacy of anti-PD-1 or anti-PD-L1 antibodies for platinum-resistant mUC. A total of six clinical trials fulfilled eligibility criteria, comprising 1,315 patients treated with PD-1/PD-L1 and 736 who received chemotherapy.

The overall likelihood of survival in patients treated by PD-1/PD-L1 blockade at 6 months was 62 percent. This dropped to 42 percent at 12 months and to 31 percent at 18 months. The restricted mean survival times (RMST) at these timepoints were 4.8, 7.8 and 10 months, respectively.

Two of the included randomized trials compared PD-1 against PD-L1 and was included in a network meta-analysis. Researchers found that RMST at 18 months was statistically comparable between the two treatments (1 month, 95 percent confidence interval [CI], –0.5 to 2.3).

Using reconstructed data from three trials exploring PD-1 blockade (n=613) vs that of three other trials of PD-L1 blockade (n=702), researchers further confirmed the comparable benefits of both treatments. RMST at 12 months of follow-up was 7.8 months for both, which then increased to 10.1 and 10 months, respectively, at 18 months of follow-up.

“We acknowledge that there could be subtle differences among different drugs within the therapeutic subclasses of PD-1 and PD-L1 inhibitors, but we were unable to address such potential differences with the available data,” said researchers. This may have implications in the future design of clinical trials.

Editor's Recommendations
Most Read Articles
Elvira Manzano, 2 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 2 days ago
For individual with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.